这些结果表明,HER2-low和HER2-negative TNBC具有不同的肿瘤进化特征。 HER2-negative TNBC高表达良好预后相关的免疫球蛋白基因 免疫球蛋白相关基因(IGKC、IGHG1、IGHG4、IGLC2等)在HER2-negative TNBC中显著上调,而APOD、MUCL1、SCGB2A1、PTN...
NGS是另一种常用的检测HER2扩增和点突变的方法,但目前尚无统一的、针对NGS检测HER2扩增的阳性判读标准。一项乳腺癌回顾性研究表明,HER2 IHC阳性(3+)的患者通过FISH检测阳性(HER2扩增)的比例为91.4%,且大部分HER2 IHC阴性(98.5%的IHC 0,93.1%的IHC 1+)乳腺...
1.Shen L, Peng Z, et al. Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA).2024 ESMO LBA60.2.Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical...
在HR阳性和HR阴性队列中，新发MBC患者的中位OS均长于复发性MBC患者（HR阳性：新发，未达到 vs 复发，45.1个月；HR阴性：新发，54.6个月 vs 复发，30.8个月）。在HR阳性队列中，接受所有一线内分泌治疗的患者的中位OS为“未达到”（95%CI，51.7-未达到），而未接受一线内分泌治疗的患者为40.1个月（...
德国绝经前 HRpos/HER2neg早期乳腺癌高复发风险患者辅助内分泌治疗的新变革 《The Breast》:Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...
O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial[J]. The Lancet Oncology, 2023, 24(1): 77...
参考文献: Stefania Morganti and others, Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies, The Oncologist, 2023;, oyad123, https://doi.org/10.1093/oncolo/oyad123
[19]Fehrenbacher L,et al.NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2.J Clin Oncol 2020 Feb 10;38(5):444–53. ...
[4] Rossi V, Sarotto I, Maggiorotto F et al (2012) Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist 17:1418–1425. [5] Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER...